中国中西医结合消化杂志2024,Vol.32Issue(5) :450-454.DOI:10.3969/j.issn.1671-038X.2024.05.15

非酒精性脂肪性肝病更名:从代谢功能障碍相关脂肪肝异质性到"同病异治"

Renaming non-alcoholic fatty liver disease:from metabolic dysfunction-associated fatty liver heterogeneity to"different treatment for the same disease"

刘嘉玲 孙劲晖
中国中西医结合消化杂志2024,Vol.32Issue(5) :450-454.DOI:10.3969/j.issn.1671-038X.2024.05.15

非酒精性脂肪性肝病更名:从代谢功能障碍相关脂肪肝异质性到"同病异治"

Renaming non-alcoholic fatty liver disease:from metabolic dysfunction-associated fatty liver heterogeneity to"different treatment for the same disease"

刘嘉玲 1孙劲晖1
扫码查看

作者信息

  • 1. 北京中医药大学东直门医院(北京,100700)
  • 折叠

摘要

关于非酒精性脂肪性肝病(NAFLD)更名为代谢功能障碍相关脂肪肝(MAFLD/MASLD)近两年来争议不断,期间大数据研究结果证明了 NAFLD的时代局限性.重新审视命名法,可以正确认识NAFLD关键致病因素、了解其异质性及不同临床表型.目前NAFLD药物疗法临床应答率不高,通过分析其异质性,结合中医"同病异治"理论为临床诊断、研究、治疗NAFLD提供参考.

Abstract

The renaming of non-alcoholic fatty liver disease(NAFLD)to metabolic dysfunction-associated fatty/steatotic liver disease(MAFLD/MAFLD)has been controversial for the last two years,during which the re-sults of big data studies have proved the age-old limitations of NAFLD.Revisiting the nomenclature will allow for a proper understanding of the key causative factors of NAFLD,and an appreciation of its heterogeneity and differ-ent clinical phenotypes.The clinical response rate of NAFLD drug therapy is not high.By analyzing its heteroge-neity and combining it with the theory of"different treatment for the same disease"in traditional Chinese medi-cine,we can provide references for clinical diagnosis,research,and treatment of NAFLD.

关键词

非酒精性脂肪性肝病/代谢性脂肪肝疾病/异质性/同病异治

Key words

non-alcoholic fatty liver disease/metabolic fatty liver disease/heterogeneity/homoeopathy

引用本文复制引用

基金项目

国家自然科学基金(81573969)

出版年

2024
中国中西医结合消化杂志
华中科技大学同济医学院,中国中西医结合学会消化系统疾病专业委员会,中华中医药学会脾胃病专业委员会

中国中西医结合消化杂志

CSTPCD
影响因子:1.363
ISSN:1671-038X
段落导航相关论文